基于99mTc-MAA的剂量学在肝脏恶性肿瘤90Y-SIRT个体化规划中的预测价值
该研究纳入79例接受90Y选择性内放射治疗(SIRT)的肝脏恶性肿瘤患者,比较治疗前99mTc-MAA SPECT/CT模拟剂量与治疗后90Y SPECT/CT实际剂量。结果显示各感兴趣区的平均吸收剂量呈强相关,但模拟倾向于高估肿瘤吸收剂量26%。剂量体积直方图指标也显示良好相关,但部分指标存在显著差异。
要点
- 99mTc-MAA模拟与90Y治疗后SPECT/CT的平均吸收剂量在所有感兴趣区呈强相关。
- 模拟倾向于高估肿瘤吸收剂量26%。
- 剂量体积直方图指标相关良好,但部分指标(主要在非肿瘤肝)存在显著差异。
核心结论
- 本研究支持基于99mTc-MAA的模拟剂量与基于90Y SPECT/CT的治疗剂量之间吸收剂量指标呈强相关,凸显99mTc-MAA不仅对平均吸收剂量、也对剂量分布的预测能力。
研究设计与样本
- 共分析79例患者,分别基于局部沉积法(Local Deposition Method)从99mTc-MAA和90Y SPECT/CT计算治疗前与治疗后三维体素剂量学。
- 对每个感兴趣区获取平均吸收剂量、肿瘤与正常组织比值及剂量体积直方图(DVH)指标并进行比较。
- 使用Mann-Whitney U检验和Pearson相关系数评估两种方法间的相关性,并探讨肿瘤肝脏体积对吸收剂量指标的影响。
主要发现
- 模拟与治疗的平均吸收剂量在所有感兴趣区均呈强相关。
- 模拟倾向于高估肿瘤吸收剂量26%。
- DVH指标也显示良好相关,但多个指标存在显著差异,主要位于非肿瘤肝。
- 观察到肿瘤肝脏体积对模拟与治疗吸收剂量指标之间的差异无显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selective internal radiation therapy with 90Y radioembolization aims to selectively irradiate liver tumours by administering radioactive microspheres under the theragnostic assumption that the pre-therapy injection of 99mTc labelled macroaggregated albumin (99mTc-MAA) provides an estimation of the 90Y microspheres biodistribution, which is not always the case. Due to the growing interest in theragnostic dosimetry for personalized radionuclide therapy, a robust relationship between the delivered and pre-treatment radiation absorbed doses is required. In this work, we aim to investigate the predictive value of absorbed dose metrics calculated from 99mTc-MAA (simulation) compared to those obtained from 90Y post-therapy SPECT/CT. RESULTS: A total of 79 patients were analysed. Pre- and post-therapy 3D-voxel dosimetry was calculated on 99mTc-MAA and 90Y SPECT/CT, respectively, based on Local Deposition Method. Mean absorbed dose, tumour-to-normal ratio, and absorbed dose distribution in terms of dose-volume histogram (DVH) metrics were obtained and compared for each volume of interest (VOI). Mann-Whitney U-test and Pearson's correlation coefficient were used to assess the correlation between both methods. The effect of the tumoral liver volume on the absorbed dose metrics was also investigated. Strong correlation was found between simulation and therapy mean absorbed doses for all VOIs, although simulation tended to overestimate tumour absorbed doses by 26%. DVH metrics showed good correlation too, but significant differences were found for several metrics, mostly on non-tumoral liver. It was observed that the tumoral liver volume does not significantly affect the differences between simulation and therapy absorbed dose metrics. CONCLUSION: This study supports the strong correlation between absorbed dose metrics from simulation and therapy dosimetry based on 90Y SPECT/CT, highlighting the predictive ability of 99mTc-MAA, not only in terms of mean absorbed dose but also of the dose distribution.
引用
- Riveira-Martin M, Akhavanallaf A, Mansouri Z, et al. Predictive value of 99mTc-MAA-based dosimetry in personalized 90Y-SIRT planning for liver malignancies. EJNMMI Res. 2023. PMID: 37395912. doi:10.1186/s13550-023-01011-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。